
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc is positioned for substantial growth within the medical technology sector, with its diverse offerings in Diagnostics, Medical Devices, and Digital Health. The company presents an attractive current valuation that aligns with its potential for significant upside, despite the inherent risks associated with early-stage commercialization. Analysts anticipate substantial revenue growth for key products like EsoGuard and the Veris Cancer Care Platform, expected to emerge prominently in 2025 and 2026.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which was significantly better than the expected loss range of $(0.13) to $(0.25). However, the company experienced a decline in the number of EsoGuard tests processed, dropping from 3,034 in Q1 to 2,756 in Q2, indicating a negative trend in product usage and demand. Additionally, multiple risks impacting the company's financial performance include liquidity concerns, challenges in demonstrating product effectiveness, regulatory hurdles, commercialization issues, and varying macroeconomic conditions, all of which contribute to a cautious outlook on PAVmed's stock.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares